Valuation: CEL-SCI Corporation

Market Cap 40.63M 36.25M 33.77M 30.73M 57.87M 3.91B 58.3M 408M 159M 2B 153M 149M 6.42B P/E 2026 *
-0.75x
P/E 2027 * -0.36x
Enterprise Value 35.08M 31.29M 29.15M 26.53M 49.96M 3.38B 50.33M 352M 137M 1.72B 132M 129M 5.54B EV / Sales 2026 *
-
EV / Sales 2027 * 5.91x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day+6.06%
1 week+42.94%
Current month+17.96%
1 month+47.27%
3 months+91.34%
6 months-43.75%
Current year-53.80%
1 week 1.7
Extreme 1.7
2.75
1 month 1.46
Extreme 1.46
2.75
Current year 0.89
Extreme 0.89
6.75
1 year 0.89
Extreme 0.89
10.7
3 years 0.89
Extreme 0.89
96.91
5 years 0.89
Extreme 0.89
384.64
10 years 0.89
Extreme 0.89
1,227.42
Manager TitleAgeSince
Chief Executive Officer 67 1994-12-31
Director of Finance/CFO 75 2024-11-12
Chief Tech/Sci/R&D Officer - 2024-04-30
Director TitleAgeSince
Director/Board Member 67 1994-12-31
Director/Board Member 73 2015-06-21
Chairman 69 2024-07-07
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Free

Chief Executive Officer

2,621 0.0149%
9/30/26 Free

Chief Financial Officer

2,082 0.0118%
9/30/26 Free

Chief Technology Officer

1,165 0.0066%
Change 5-day change 1-year change 3-year change Capi.($)
+6.06%+42.94%-75.94%-92.57% 40.63M
+4.16%+3.04%+49.37%+94.17% 74.16B
-0.37%-3.81%+19.51%+78.12% 57.39B
+1.63%-1.61%+3.16%+36.89% 47.64B
-0.42%+1.41%+339.21%+709.92% 44.29B
+1.95%-2.88%+28.36%+33.03% 42.5B
+0.76%-2.00%+4.40%+110.74% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+4.53%+31.34%+26.92% 28.53B
+0.24%-2.16%-7.82%-11.75% 24.34B
Average +1.50%+3.30%+40.09%+103.95% 39.06B
Weighted average by Cap. +1.25%-0.84%+57.17%+135.01%

Financials

2026 *2027 *
Net sales - 5.97M 5.33M 4.96M 4.52M 8.51M 575M 8.57M 59.97M 23.33M 294M 22.42M 21.94M 944M
Net income -25.08M -22.38M -20.85M -18.97M -35.73M -2.42B -35.99M -252M -98.01M -1.23B -94.17M -92.13M -3.96B -29.51M -26.33M -24.53M -22.32M -42.04M -2.84B -42.35M -296M -115M -1.45B -111M -108M -4.66B
Net Debt -5.55M -4.95M -4.62M -4.2M -7.91M -535M -7.97M -55.78M -21.7M -273M -20.85M -20.4M -878M -5.34M -4.76M -4.44M -4.04M -7.6M -514M -7.66M -53.62M -20.86M -262M -20.04M -19.61M -844M
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
44
Date Price Change Volume
26-10-05 US$2.430 +5.19% 502,539
26-10-02 US$2.310 +10.53% 395,180
26-10-01 US$2.090 +1.46% 810,343
26-09-30 US$2.060 +15.08% 479,379
26-09-29 US$1.790 +5.29% 75,217
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.310USD
Average target price
12.50USD
Spread / Average Target
+441.13%

Annual profits - Rate of surprise